Opinion and Comment

バイオ企業と製薬企業の商品開発のベンチマーキング

Nature Biotechnology 32, 7 doi: 10.1038/nbt.2947

The biotech sector's record in originating high-priority medicines exceeds that of the pharmaceutical industry, its costs are lower and its products have comparable revenues.

目次へ戻る

プライバシーマーク制度